ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last3,061 to 3,080 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Anti-hypertensive Therapy to Goal <140/90 mmHg vs No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg: serious adverse events113 of 1,208

126 of 1,200

-1.1 points

-3.5 to 1.2

2,408NCT02299414

Chronic Hypertension and Pregnancy (CHAP) Project

CHARM2 Intervention vs Control: deaths from any cause3 of 1,200

3 of 1,202

0.0 points

-0.5 to 0.5

2,402NCT03514914

Enhancing Male Participation in Interventions to Prevent Unintended Pregnancy

QIVc vs Comparator QIV: deaths from any cause2 of 1,597

0 of 805

0.1 points

-0.4 to 0.5

2,402NCT04074928

Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects

QIVc vs Comparator QIV: serious adverse events15 of 1,597

7 of 805

0.1 points

-0.9 to 0.8

2,402NCT04074928

Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects

Absorb BVS vs XIENCE: Number of Participants With Repeat Coronary Arteriography186 of 1,186

188 of 1,212

0.2 points

-2.7 to 3.1

2,398NCT02173379

Absorb IV Randomized Controlled Trial

V114 vs Prevnar 13™: serious adverse events192 of 1,965

45 of 433

-0.6 points

-4.1 to 2.3

2,398NCT03692871

A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)

Alert vs Usual Care: Death71 of 1,201

61 of 1,192

0.8 points

-1.0 to 2.6

2,393NCT01862419

An Electronic Alert System for In-Hospital Acute Kidney Injury

Alert vs Usual Care: Dialysis Within 7 Days87 of 1,201

70 of 1,192

1.4 points

-0.6 to 3.4

2,393NCT01862419

An Electronic Alert System for In-Hospital Acute Kidney Injury

Canadian C-Spine Rule vs Control Phase (Usual Care): Proportion of Patients Feeling Uncomfortable654 of 1,108

883 of 1,285

-9.7 points

-13.5 to -5.8

2,393NCT02786966

A Pragmatic Evaluation of the Canadian C-Spine Rule by Paramedics

Absorb BVS vs XIENCE: Number of Participants With Target Vessel Revascularization (TVR)91 of 1,189

81 of 1,200

0.9 points

-1.2 to 3.0

2,389NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI171 of 1,189

155 of 1,200

1.5 points

-1.3 to 4.2

2,389NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Target Lesion Revascularization (TLR)114 of 1,189

82 of 1,200

2.8 points

0.6 to 5.0

2,389NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With ID-TVR Excluding TLR89 of 1,189

80 of 1,200

0.8 points

-1.2 to 2.9

2,389NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)262 of 1,189

240 of 1,200

2.0 points

-1.2 to 5.3

2,389NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Target Vessel Myocardial Infarction (TV-MI)134 of 1,189

106 of 1,200

2.4 points

0.0 to 4.9

2,389NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced All Death/All MI209 of 1,189

188 of 1,200

1.9 points

-1.1 to 4.9

2,389NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants With Ischemia Driven TLR (ID-TLR)111 of 1,189

82 of 1,200

2.5 points

0.3 to 4.7

2,389NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Death (Cardiac, Vascular, Non-cardiovascular)77 of 1,189

72 of 1,200

0.5 points

-1.5 to 2.4

2,389NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)233 of 1,189

207 of 1,200

2.3 points

-0.8 to 5.5

2,389NCT02173379

Absorb IV Randomized Controlled Trial

Absorb BVS vs XIENCE: Number of Participants Experienced Death/All MI/All Revascularization (DMR)310 of 1,189

284 of 1,200

2.4 points

-1.1 to 5.9

2,389NCT02173379

Absorb IV Randomized Controlled Trial

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=154"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=154

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02299414-sae",
        "title": "Anti-hypertensive Therapy to Goal <140/90 mmHg vs No Anti-hypertensive Unless BP is Severe (≥160/105 mmHg: serious adverse events",
        "summary": "113 of 1208 against 126 of 1200; risk difference -1.1 points, 95% interval -3.5 to 1.2; NCT02299414, Chronic Hypertension and Pregnancy (CHAP) Project",
        "record": "/library/comparisons/NCT02299414-sae",
        "nct_id": "NCT02299414",
        "kind": "serious-adverse-events",
        "participants": 2408,
        "risk_difference": {
          "value": -0.011456953642384096,
          "lower": -0.035468434674659,
          "upper": 0.012496492166721874
        },
        "group_1": "113 of 1,208",
        "group_2": "126 of 1,200",
        "difference": "-1.1 points",
        "interval": "-3.5 to 1.2",
        "trial_title": "Chronic Hypertension and Pregnancy (CHAP) Project"
      },
      {
        "id": "NCT03514914-deaths",
        "title": "CHARM2 Intervention vs Control: deaths from any cause",
        "summary": "3 of 1200 against 3 of 1202; risk difference 0.0 points, 95% interval -0.5 to 0.5; NCT03514914, Enhancing Male Participation in Interventions to Prevent Unintended Pregnancy",
        "record": "/library/comparisons/NCT03514914-deaths",
        "nct_id": "NCT03514914",
        "kind": "deaths",
        "participants": 2402,
        "risk_difference": {
          "value": 0.00000415973377703837,
          "lower": -0.005086916959551913,
          "upper": 0.005101902963710504
        },
        "group_1": "3 of 1,200",
        "group_2": "3 of 1,202",
        "difference": "0.0 points",
        "interval": "-0.5 to 0.5",
        "trial_title": "Enhancing Male Participation in Interventions to Prevent Unintended Pregnancy"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=155",
  "request_id": "t1YCH2QmonAsglYS"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?